The Effects of Long Term Inhalation of Hypertonic Saline in Subjects With Cystic Fibrosis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00271310
Recruitment Status :
First Posted : December 30, 2005
Last Update Posted : October 9, 2006
Royal Prince Alfred Hospital, Sydney, Australia
Cystic Fibrosis Foundation
National Health and Medical Research Council, Australia
The effect of long term inhalation of hypertonic saline in subjects with cystic fibrosis on lung function, incidence of respiratory tract infections, quality of life, quantitative microbiology and sputum cytokine profile. The hypothesis is that regular inhalation of nebulised hypertonic saline will have a beneficial effect on lung function and other clinical outcomes with no adverse effects on infection and inflammation in adults and children with cystic fibrosis.
Condition or disease
Drug: hypertonic saline
The study intervention is nebulised hypertonic (7%) saline (Active) or nebulised normal (0.9%) saline (Control) twice per day for 336 days. At a screening visit, subjects will complete quality of life questionnaires, be questioned regarding their medical history, undergo physical examination and spirometry, and will be requested to provide a sputum sample. The subject is then supervised taking their first dose to ensure the correct procedure is used and there are no adverse effects. The subject then commences taking the trial solution at home, and once a week completes a diary card to monitor factors such as respiratory tract infections and medication use. Subsequent visits are scheduled at Days 28, 84, 168, 252, 334, and 336, at which the same investigation are performed as at the screening visit.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
6 Years and older (Child, Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Confirmed diagnosis of CF (sweat tests/genotype)
The subject, or their legal guardian for children under 18 years old, must provide written informed consent.
The subject must be in stable clinical condition at the time of and for a period of 14 days prior to their recruitment into the study.
Age > 6 years old
FEV1 > 40% predicted for height, age and gender
Proven or anticipated compliance with therapy or study protocol
Regular attendee at a Cystic Fibrosis Clinic (> 2 visits per year)
Able to reproducibly perform lung function tests (spirometry)
Relatively stable nutritional status (< 2 kg weight loss in last 6 months and < 5 kg weight loss in last year)
Known to have “normal” (for CF subject) laboratory tests - haematology, biochemistry, immunology, coagulation, etc.
Requiring home oxygen (pO2 <55mmHg or pCO2 >50mmHg) or assisted ventilation.
Considered “terminally ill” or listed for transplantation (either lung or liver). Subjects that are listed for transplant after being enrolled in the trial are eligible to continue in the trial.
Subjects colonised with Burkholderia cepacia. However, if a subject becomes colonised with B. cepacia during the trial, they should continue in the trial. Subjects should be considered to be B. cepacia positive if they have had even a single lifetime isolate. In these subjects, spirometry should be measured on a dedicated spirometer.
Exposure to investigational drugs within the past 30 days.
Major haemoptysis (> 60 mL in a single episode) within the last twelve months.